Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Enorama Pharma AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ERMA vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB (OSTO:ERMA) has a Buyback Yield % of -114.95 as of Jul. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Enorama Pharma AB and its competitors. According to the industry distribution chart, Enorama Pharma AB ranks #285 out of 291 companies in the Drug Manufacturers industry, placing it in the top 97.9%.
Is Enorama Pharma AB's Buyback Yield % too high?
Enorama Pharma AB's current Buyback Yield % is -114.95. Based on the distribution chart, Enorama Pharma AB ranks #285 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #285 out of 291 companies for Buyback Yield %. This places Enorama Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Enorama Pharma AB and its competitors. Enorama Pharma AB's current Buyback Yield % is -114.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.41, compared to a current price of kr0.26 — trading 36.6% below its estimated fair value. The current Buyback Yield % is -114.95. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Buyback Yield % is -114.95 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.26 is trading 36.6% below its estimated GF Value™ of kr0.41.
GuruFocus considers Enorama Pharma AB to be Possible Value Trap.
Key valuation signals for OSTO:ERMA:
Buyback Yield %: -114.95
GF Value™: kr0.41 vs. price of kr0.26 (36.6% below fair value)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score
Get the complete analysis for OSTO:ERMA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
